Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
Key Details
- 1RECTIFIER, developed at Mass General Brigham, leverages Retrieval-Augmented Generation (RAG) AI to assess patient eligibility for clinical trials via EHRs, including unstructured notes and reports.
- 2In a 2024 NEJM AI study, RECTIFIER outperformed manual screening methods for a heart failure trial at lower cost.
- 3A randomized-controlled trial involving nearly 4,500 patients showed RECTIFIER doubled the enrollment rate compared to manual screening, with no differences across demographic groups.
- 4RECTIFIER is in use for over 20 clinical and research applications including oncology, neurology, pathology, and cardiology.
- 5Mass General Brigham Innovation facilitated the spinout, aiming for broader deployment across health systems via the AIwithCare platform.
- 6RECTIFIER is also being applied to population health and referral triage, showing >94% accuracy in select use cases.
Why It Matters

Source
EurekAlert
Related News

AI Method Protects Sensitive Data in ECGs While Retaining Clinical Value
Researchers developed an AI model (PP-VAE) that safeguards sensitive personal data in electrocardiograms without sacrificing clinical utility.

AI Predicts Brain Tumor Risks from Routine Pathology Slides
Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.

Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.